Inhibition of T cells provides protection against early invasive pneumococcal disease

Infection and Immunity

Volumn 78, Issue 12, 2010, Pages 5287-5294

  LeMessurier, Kim ^a   Häcker, Hans ^a   Tuomanen, Elaine ^a   Redecke, Vanessa ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD4 ANTIBODY; CD69 ANTIGEN; CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RESPONSE; FLOW CYTOMETRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INVASIVE PNEUMOCOCCAL DISEASE; LUNG; LUNG LAVAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL SEPSIS; PRIORITY JOURNAL; SEPSIS; SPLEEN; STREPTOCOCCUS PNEUMONIAE; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYCLOSPORINE; CYTOKINES; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; LUNG; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PNEUMOCOCCAL INFECTIONS; POLYMERASE CHAIN REACTION; SPLEEN; STREPTOCOCCUS PNEUMONIAE;

EID: 78649945619     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00431-10     Document Type: Article

References (50)

1. AlonsoDeVelasco, E., A. F. Verheul, J. Verhoef, and H. Snippe. 1995. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 59:591-603.
2. Austrian, R. 1986. Some aspects of the pneumococcal carrier state. J. Antimicrob. Chemother. 18(Suppl. A):35-45.
3. Basset, A., C. M. Thompson, S. K. Hollingshead, D. E. Briles, E. W. Ades, M. Lipsitch, and R. Malley. 2007. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect. Immun. 75:5460-5464.
4. Bergeron, Y., N. Ouellet, A. M. Deslauriers, M. Simard, M. Olivier, and M. G. Bergeron. 1998. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect. Immun. 66:912-922.
5. Bigbee, C. L., D. G. Gonchoroff, G. Vratsanos, S. G. Nadler, H. G. Haggerty, and J. L. Flynn. 2007. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 56:2557-2565.
6. Bikoff, E. K., L. Y. Huang, V. Episkopou, J. van Meerwijk, R. N. Germain, and E. J. Robertson. 1993. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J. Exp. Med. 177:1699-1712.
7. Black, S., E. K. France, D. Isaacman, L. Bracken, E. Lewis, J. Hansen, B. Fireman, R. Austrian, J. Graepel, S. Gray, and N. P. Klein. 2007. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26:771-777.
8. Cao, J., Y. Gong, D. Li, N. Yin, T. Chen, W. Xu, X. Zhang, and Y. Yin. 2009. CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. Vaccine 27:2838-2844.
9. Catterall, J. R. 1999. Streptococcus pneumoniae. Thorax 54:929-937.
10. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
11. Dowell, S. F., J. C. Butler, G. S. Giebink, M. R. Jacobs, D. Jernigan, D. M. Musher, A. Rakowsky, and B. Schwartz. 1999. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J. 18:1-9.
12. Duong, M., M. Simard, Y. Bergeron, and M. G. Bergeron. 2001. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob. Agents Chemother. 45:252-262.
13. Emmel, E. A., C. L. Verweij, D. B. Durand, K. M. Higgins, E. Lacy, and G. R. Crabtree. 1989. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246:1617-1620.
14. Feldman, C., and R. Anderson. 2009. New insights into pneumococcal disease. Respirology 14:167-179.
15. Geng, L., S. Dong, Y. Fang, G. Jiang, H. Xie, M. Shen, S. Yan, and S. Zheng. 2008. Cyclosporin A up-regulates B7-DC expression on dendritic cells in an IL-4-dependent manner in vitro, which is associated with decreased allostimulatory capacity of dendritic cells. Immunopharmacol. Immunotoxicol. 30:399-409.
16. + T cells in major histocompatibility complex class II-deficient mice. Science 253:1417-1420.
17. Hogberg, L., P. Geli, H. Ringberg, E. Melander, M. Lipsitch, and K. Ekdahl. 2007. Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J. Clin. Microbiol. 45:948-952.
18. Hwang, I. K., S. S. Yi, J. H. Shin, K. Y. Yoo, J. H. Choi, C. H. Lee, J. K. Seong, Y. S. Yoon, J. H. Park, and M. H. Won. 2010. Cyclosporine A reduces dendritic outgrowth of neuroblasts in the subgranular zone of the dentate gyrus in C57BL/6 mice. Neurochem Res. 35:465-472.
19. Kadioglu, A., W. Coward, M. J. Colston, C. R. Hewitt, and P. W. Andrew. 2004. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72:2689-2697.
20. Kadioglu, A., N. A. Gingles, K. Grattan, A. Kerr, T. J. Mitchell, and P. W. Andrew. 2000. Host cellular immune response to pneumococcal lung infection in mice. Infect. Immun. 68:492-501.
21. Kaplan, S. L., W. J. Barson, P. L. Lin, S. H. Stovall, J. S. Bradley, T. Q. Tan, J. A. Hoffman, L. B. Givner, and E. O. Mason, Jr. 2010. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 125:429-436.
22. Kockx, M., D. L. Guo, M. Traini, K. Gaus, J. Kay, S. Wimmer-Kleikamp, C. Rentero, J. R. Burnett, W. Le Goff, M. Van Eck, J. L. Stow, W. Jessup, and L. Kritharides. 2009. Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway. J. Biol. Chem. 284:24144-24154.
23. Kremer, J. M., M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy, S. Steinfeld, E. Tindall, J. C. Becker, T. Li, I. F. Nuamah, R. Aranda, and L. W. Moreland. 2005. Treatment of rheumatoid arthritis with the selective co-stimulation modulator Abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52:2263-2271.
24. Lexau, C. A., R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M. M. Farley, L. H. Harrison, W. Schaffner, A. Reingold, N. M. Bennett, J. Hadler, P. R. Cieslak, and C. G. Whitney. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043-2051.
25. Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815.
26. Mbelle, N., R. E. Huebner, A. D. Wasas, A. Kimura, I. Chang, and K. P. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1171-1176.
27. McCullers, J. A., and E. I. Tuomanen. 2001. Molecular pathogenesis of pneumococcal pneumonia. Front Biosci. 6:D877-D889.
28. + T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl. Acad. Sci. U. S. A. 103:10408-10413.
29. Musher, D. M. 1992. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14:801-807.
30. Nolan, A., M. Weiden, A. Kelly, Y. Hoshino, S. Hoshino, N. Mehta, and J. A. Gold. 2008. CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis. Am. J. Respir. Crit. Care Med. 177:301-308.
31. Orihuela, C. J., G. Gao, M. McGee, J. Yu, K. P. Francis, and E. Tuomanen. 2003. Organ-specific models of Streptococcus pneumoniae disease. Scand. J. Infect. Dis. 35:647-652.
32. Pallares, R., J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
33. Rosch, J. W., J. Sublett, G. Gao, Y. D. Wang, and E. I. Tuomanen. 2008. Calcium efflux is essential for bacterial survival in the eukaryotic host. Mol. Microbiol. 70:435-444.
34. Roush, S. W., and T. V. Murphy. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155-2163.
35. Saha, B., B. Jaklic, D. M. Harlan, G. S. Gray, C. H. June, and R. Abe. 1996. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J. Immunol. 157:3869-3875. (Pubitemid 126449294)
36. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
37. Schaaf, B. M., F. Boehmke, H. Esnaashari, U. Seitzer, H. Kothe, M. Maass, P. Zabel, and K. Dalhoff. 2003. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am. J. Respir. Crit. Care Med. 168:476-480.
38. Schlichting, C. L., W. D. Schareck, and M. Weis. 2005. Dendritic cell adhesion is enhanced on endothelial cells preexposed to calcineurin inhibitors. J. Cardiovasc. Pharmacol. 46:250-254.
39. Schuchat, A., K. Robinson, J. D. Wenger, L. H. Harrison, M. Farley, A. L. Reingold, L. Lefkowitz, and B. A. Perkins. 1997. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med. 337:970-976.
40. Shaw, J. P., P. J. Utz, D. B. Durand, J. J. Toole, E. A. Emmel, and G. R. Crabtree. 1988. Identification of a putative regulator of early T cell activation genes. Science 241:202-205.
41. Steenhoff, A. P., S. S. Shah, A. J. Ratner, S. M. Patil, and K. L. McGowan. 2006. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin. Infect. Dis. 42:907-914.
42. Sun, K., S. L. Salmon, S. A. Lotz, and D. W. Metzger. 2007. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun. 75:1196-1202.
43. Trzcinski, K., C. Thompson, R. Malley, and M. Lipsitch. 2005. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect. Immun. 73:7043-7046.
44. van der Poll, T., A. Marchant, C. V. Keogh, M. Goldman, and S. F. Lowry. 1996. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis. 174:994-1000.
45. van der Sluijs, K. F., L. J. van Elden, M. Nijhuis, R. Schuurman, J. M. Pater, S. Florquin, M. Goldman, H. M. Jansen, R. Lutter, and T. van der Poll. 2004. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 172:7603-7609.
46. van Rossum, A. M., E. S. Lysenko, and J. N. Weiser. 2005. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect. Immun. 73:7718-7726.
47. van Schaik, S. M., and A. K. Abbas. 2007. Role of T cells in a murine model of Escherichia coli sepsis. Eur. J. Immunol. 37:3101-3110.
48. Wallace, P. M., J. N. Rodgers, G. M. Leytze, J. S. Johnson, and P. S. Linsley. 1995. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 154:5885-5895.
49. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
50. Yamamoto, N., K. Kawakami, Y. Kinjo, K. Miyagi, T. Kinjo, K. Uezu, C. Nakasone, M. Nakamatsu, and A. Saito. 2004. Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma. Microbes Infect. 6:1241-1249.